FIG 1.

Summary of tumor mutation burden in the protocol patient population after excluding patients who had alterations in actionable genes detected in the smaller sequencing panel. (A) Overall distribution of tumor alterations, with patients arranged horizontally and genes vertically. (B) Total number of gene alterations per tumor ranged from zero to more than 250, with a mean of 5.1 alterations per tumor. (C) Only 96 of 409 genes on the next-generation sequencing panel were considered clinically actionable. On average, only one alteration in an actionable gene per tumor was detected. (D) On average, only 0.4 actionable alterations—mutation or amplification in an actionable gene that is known or has inferred biologic function—were detected per tumor. The majority of alterations in actionable genes identified were variants of unknown significance. HN, head and neck; PS, performance status; q, quartile.